Chesterbrook-based AmerisourceBergen has agreed to pay $625 million to settle the civil fraud charges brought against it by the Justice Department, writes John George for the Philadelphia Business Journal.

The allegations included charges that the company operated a facility where it repackaged oncology-supportive injectable drugs into pre-filled syringes. The Justice Department says these were then improperly distributed to physicians treating cancer patients.

“By resolving this matter and entering into the corporate integrity agreement, AmerisourceBergen acknowledged that some of its practices at its Medical Initiatives division were not consistent with AmerisourceBergen’s approach to corporate compliance,” the company said.

According to AmerisourceBergen, Medical Initiatives was voluntarily closed four years ago. By entering into the corporate integrity agreement now, AmerisourceBergen said it is confirming its commitment to compliance and the constant evaluation and enhancement of its compliance programs.

“AmerisourceBergen is not aware of, and did not admit to any conduct pertaining to, evidence that any patient was harmed by the administration of a Medical Initiatives pre-filled syringe,” the company said.

AmerisourceBergen subsidiary AmerisourceBergen Specialty Group already agreed to pay $260 million last year to resolve any criminal liability after pleading guilty to illegally distributing misbranded drugs.

Read more about the settlement in the Philadelphia Business Journal here.

[uam_ad id=”80503″]

.

[uam_ad id=”80502″]